Friday Pop Quiz 2/27/2026
What is the most common site of extracutaneous involvement in this non-infectious disease?
A. Lungs
B. Eyes
C. Bone Marrow
D. Liver
E. Nasal mucosa
To find out the correct answer and read the explanation, click here.
Brought to you by our brand partner
*Brand partners had no involvement in the content of the questions or answers. …
What is the most common site of extracutaneous involvement in this non-infectious disease?
A. Lungs
B. Eyes
C. Bone Marrow
D. Liver
E. Nasal mucosa
To find out the correct answer and read the explanation, click here.
Brought to you by our brand partner
*Brand partners had no involvement in the content of the questions or answers. … 
Transitioning from a third-year residency into the professional workforce is a major milestone that requires a strategic approach. Unlike fellowship tracks, which offer an additional year of buffer, going straight into the workforce demands immediate and thoughtful preparation. By following these core principles, you can navigate the complexities of the job market and secure a position that aligns … 
When a patient reveals they went online for health information, it’s tempting for a clinician to inwardly groan. Fears of self-diagnosis or misinformation about diagnosed conditions can make clinicians concerned when patients seek medical information through online forums and social media. Yet these virtual communities are incredibly popular, most notably Reddit and its discussion forums.
A … 
At the 2026 ODAC Dermatology Conference, we had the privilege of learning about chronic spontaneous urticaria (CSU) from Dr. Adam Friedman, MD, FAAD, Professor and Chair of Dermatology at The George Washington University School of Medicine. CSU can be a maddening, exhausting condition for patients, with a relapsing disease course and without identifiable triggers. Given that symptoms are often abs … 
Tacrolimus and Pimecrolimus are both calcineurin inhibitors FDA-approved for atopic dermatitis. However, their topical use offers steroid-sparing benefits for a wide variety of other inflammatory dermatologic conditions. Tacrolimus was discovered in 1984 from the soil bacterium Streptomyces tsukubaensis and was originally FDA approved in 1994 as a systemic immunosuppressant for organ transplanta …